Cochrane Database of Systematic Reviews 2021, Issue 2. Art. No.: CD009593. DOI: 10.1002/14651858.CD009593.pub5.
Serie: Documentos Técnico
Department of AIDS Control
Ministry of Health & Family Welfare
Clinical guideline | Published: 11 January 2012 | nice.org.uk/guidance/cg137
Este documento apresenta uma orientação provisória aos laboratórios e diferentes atores envolvidos na realização de exames laboratoriais para o vírus COVID-19. Ele baseia-se parcialmente na orientação provisória para os exames laboratoriais do coronavírus da Síndrome Respiratória do Ori...ente Médio (MERS).1-6 As informações sobre a infecção em humanos pelo vírus COVID-19 estão evoluindo e a OMS continua a monitorar os acontecimentos e revisar as recomendações conforme necessário. Este documento será revisado conforme novas informações forem disponibilizadas.
more
Cochrane Database Syst Rev. 2016 Jul 1; (6): 1–61 -Published online 2016 July 1
Due to the particular Amazonian situation of vectorial transmission based mostly on the wild cycle of Trypanosoma cruzi with diversity of triatomine vectors involved in effective transmission, and the variety of eco-epidemiological situations that facilitate such transmission, the countries of the A...mazon agreed that the development and strengthening of preventive actions based on comprehensive surveillance and detection of effective vectorial transmission, based on mandatory notification of acute or chronic cases, was required. In addition, it was recommended that surveillance and prevention and/or vector control actioDue to the particular Amazonian situation of vectorial transmission based mostly on the wild cycle of Trypanosoma cruzi with diversity of triatomine vectors involved in effective transmission, and the variety of eco-epidemiological situations that facilitate such transmission, the countries of the Amazon agreed that the development and strengthening of preventive actions based on comprehensive surveillance and detection of effective vectorial transmission, based on mandatory notification of acute or chronic cases, was required.
more
- The goal of diagnostic testing for Ebola and Marburg virus diseases is to identify cases to provide timely and appropriate care and to stop disease transmission.
- All individuals meeting the case definition for Ebola or Marburg virus diseases should be tested.
- The recommended sample type ...for testing for orthoebolaviruses and orthomarburgviruses is whole blood or plasma for living patients, and oral swab for deceased individuals.
- Laboratory confirmation of Orthoebolavirus and Orthomarburgvirus infections and further species identification should be done using nucleic acid amplification testing (NAAT).
- If a suspected case tests negative (living patient) and the blood was drawn less than 72 hours after symptom onset, a second test should be performed with blood drawn more than 72 hours after symptom onset.
- All manipulations in laboratory settings of samples originating from suspected, probable or confirmed cases of Ebola and Marburg virus diseases should be conducted with appropriate biosafety measures according to a risk-based approach.
- Whole or partial genome sequencing can be used to characterize viruses and complement epidemiologic investigations.
- Member States are strongly encouraged to share genetic sequence data (GSD) in publicly accessible databases.
- Member States are required to immediately notify the World Health Organization (WHO) under the International Health Regulations (IHR) 2005 of positive laboratory results.
more
This guide is available in following languages:
Arabic, German, English, French, Italien, Persian, Polish, Russian, Serbian, Croatian, Spanish, Turkish. Go to http://www.ethno-medizinisches-zentrum.de/index.php?option=com_content&view=article&id=37&Itemid=40
a dernière mise à jour a été effectuée dans le livret de la PCIME en 2014, mais depuis lors, des mises à jour importantes ont été effectuées sur la prise en charge du jeune nourrisson malade (MJN) âgé de moins de 2 mois. Cette mise à jour 2019 de la section sur le jeune enfant malade Pri...se en charge du jeune enfant malade âgé de moins de 2 mois : IMCI chart booklet. remplace le IMCI chart booklet de 2014. Les nouvelles mises à jour reflètent les récentes lignes directrices sur la prise en charge des infections bactériennes graves possibles (IPSP) chez les jeunes nourrissons lorsque l'orientation vers un spécialiste n'est pas possible, publiées en 2015. Elles comprennent l'évaluation, la classification et l'orientation de la SYI avec PSBI ; et le traitement ambulatoire de la SYI avec infection locale ou respiration rapide (pneumonie) chez les nourrissons âgés de 7 à 59 jours. Les autres mises à jour comprennent : une nouvelle section sur la manière de réévaluer, de classer et de traiter la SYI avec PSBI lorsque l'orientation n'est pas possible dans les établissements de santé ambulatoires par des agents de santé formés à la PCIME ; des changements dans l'évaluation et la prise en charge des jeunes nourrissons pour l'infection par le VIH ; et l'identification des nourrissons de moins de 7 jours de qui ont besoin de soins kangourou.
more